Tesamorelin

Where to Inject Tesamorelin

Tesamorelin (Egrifta) is an FDA-approved GHRH analog for HIV-associated lipodystrophy. It is administered as a once-daily subcutaneous abdominal injection.

Recommended Injection Sites

Abdomen

Primary

The only recommended injection site per FDA labeling. Tesamorelin specifically targets abdominal fat.

Angle90°

Depth8-12mm

TipRotate among abdominal quadrants. Stay 2+ inches from navel, avoid scar tissue and belt line.

Injection Technique

Subcutaneous (SubQ)Needle: 27G (provided in kit) gauge, 12.7mm (1/2")

Wash Hands

Wash hands with soap and water for 20+ seconds. Dry with a clean towel.

Prepare the Dose

Wipe the vial stopper with alcohol. Draw the calculated dose into an insulin syringe. Remove air bubbles.

Clean the Site

Swab the injection site with alcohol in a circular motion. Allow to air dry for 30 seconds.

Pinch and Insert

Pinch a fold of skin at the injection site. Insert the needle at 90 degrees with a quick, smooth motion.

Inject Slowly

Push the plunger slowly over 5-10 seconds. Wait 5 seconds, then withdraw. Apply gentle pressure.

Dispose Safely

Place the syringe directly into a sharps container. Return the vial to the refrigerator.

Timing & Frequency

Timing

Once daily, at the same time each day. Can be morning or evening.

Frequency

Once daily subcutaneous injection.

Site Rotation

Rotate among the 4 abdominal quadrants. The abdomen is the only approved site.

Local vs Systemic Effects

Tesamorelin targets GH release from the pituitary (systemic effect) but is specifically studied for reducing abdominal visceral fat. The abdominal injection site is per FDA labeling, though systemic effects occur regardless of site.

Warnings & Precautions

!Tesamorelin is a prescription medication.
!FDA-approved only for HIV-associated lipodystrophy.
!Abdomen is the only approved injection site.
!Contains mannitol—some subjects report injection site stinging.

Frequently Asked Questions

Why is the abdomen the only approved site for tesamorelin?

Clinical trials for Egrifta only studied abdominal injection. The drug targets abdominal visceral fat. While the mechanism is systemic (pituitary GH release), the labeling restricts to the studied site.

Tesamorelin Research Guide

Full guide on Tesamorelin including benefits, dosage, and research.

General Injection Technique

Step-by-step guide covering proper injection technique and safety.

Peptide Dosage Calculator

Use our free calculator to determine the correct dosage, reconstitution volume, and injection amount for Tesamorelin.